title: How can vaccines against influenza and other viral diseases be made more effective?
authors.affiliation: Biological Mimetics, Inc., Frederick, Maryland, United States of America.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Nara
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Tobin
authors.forename: A Ray
authors.initials: AR
authors.lastname: Chaudhuri
authors.forename: Jessie D
authors.initials: JD
authors.lastname: Trujillo
authors.forename: George
authors.initials: G
authors.lastname: Lin
authors.forename: Michael W
authors.initials: MW
authors.lastname: Cho
authors.forename: Simon A
authors.initials: SA
authors.lastname: Levin
authors.forename: Wilfred
authors.initials: W
authors.lastname: Ndifon
authors.forename: Ned S
authors.initials: NS
authors.lastname: Wingreen
mesh_terms: D006801:Humans; D007252:Influenza Vaccines / Q000627:therapeutic use; D009975:Orthomyxoviridae / Q000235:genetics / Q000276:immunology*; D014611:Vaccination; D014765:Viral Vaccines / Q000627:therapeutic use*; D014777:Virus Diseases / Q000453:epidemiology / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control*
chemical_list: D007252:Influenza Vaccines; D014765:Viral Vaccines